TITLE:
Enzalutamide Associated with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Overlap: A Case Report
AUTHORS:
Sharjeel Israr, Christopher R. Mellon, Hayley J. Springs, Asia N. Quan, Marc R. Matthews
KEYWORDS:
Prostate Cancer, Enzalutamide, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, SJS/TEN
JOURNAL NAME:
Surgical Science,
Vol.12 No.12,
December
31,
2021
ABSTRACT: Enzalutamide is a hormonal therapy that blocks the action of androgens,
such as testosterone in the treatment of metastatic castration-resistant
prostate cancer. Stevens-Johnson syndrome and toxic
epidermal necrolysis (SJS/TEN) overlap and are part of an adverse drug
reaction continuum of disease, in which there is a 10% - 30% involvement of the
skin surface with mucositis, blisters, skin slough, and a macular rash. A
66-year-old male was treated with enzalutamide for metastatic prostate cancer
and developed SJS/TEN overlap with 25% total body surface area skin
involvement. The patient received a seven-day
course of cyclosporine to which he responded by re-epithelialization but
succumbed to multi-organ failure. While SJS/TEN has been reported with
apalutamide, to our knowledge, this is the first case of SJS/TEN overlap with
enzalutamide.